83 related articles for article (PubMed ID: 38499619)
1. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
Li Y; Wang N; Huang Y; He S; Bao M; Wen C; Wu L
Cancer Genet; 2024 Jun; 284-285():34-42. PubMed ID: 38626533
[TBL] [Abstract][Full Text] [Related]
2. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Hu B; Wiesehöfer M; de Miguel FJ; Liu Z; Chan LH; Choi J; Melnick MA; Arnal Estape A; Walther Z; Zhao D; Lopez-Giraldez F; Wurtz A; Cai G; Fan R; Gettinger S; Xiao A; Yan Q; Homer R; Nguyen DX; Politi K
Cancer Res; 2024 Apr; 84(8):1303-1319. PubMed ID: 38359163
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Chemotherapy Efficacy in Cervical Cancer via MAPK Pathway Inhibition by Osimertinib.
Hu Y; Hu C
Cancer Invest; 2024 May; 42(5):425-434. PubMed ID: 38818695
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomics coupled with proteomics reveals osimertinib-induced myocardial mitochondrial dysfunction.
Yang H; Qiu S; Yao T; Liu G; Liu J; Guo L; Shi C; Xu Y; Ma J
Toxicol Lett; 2024 Jun; 397():23-33. PubMed ID: 38734218
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
6. Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
La Monica S; Vacondio F; Eltayeb K; Lodola A; Volta F; Viglioli M; Ferlenghi F; Galvani F; Galetti M; Bonelli M; Fumarola C; Cavazzoni A; Flammini L; Verzè M; Minari R; Petronini PG; Tiseo M; Mor M; Alfieri R
Sci Rep; 2024 Mar; 14(1):6491. PubMed ID: 38499619
[TBL] [Abstract][Full Text] [Related]
7. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
8. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
[TBL] [Abstract][Full Text] [Related]
10. Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
Han R; Lin C; Lu C; Wang Y; Kang J; Hu C; Dou Y; Wu D; He T; Tang H; Zheng J; Li L; He Y
Cancer Lett; 2024 Apr; 588():216762. PubMed ID: 38408602
[TBL] [Abstract][Full Text] [Related]
11. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
12. Best Supportive Care of the Patient with Oesophageal Cancer.
Pichel RC; Araújo A; Domingues VDS; Santos JN; Freire E; Mendes AS; Romão R; Araújo A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551753
[TBL] [Abstract][Full Text] [Related]
13. Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways.
Cumin C; Huang YL; Rossdam C; Ruoff F; Céspedes SP; Liang CY; Lombardo FC; Coelho R; Rimmer N; Konantz M; López MN; Alam S; Schmidt A; Calabrese D; Fedier A; Vlajnic T; von Itzstein M; Templin M; Buettner FFR; Everest-Dass A; Heinzelmann-Schwarz V; Jacob F
Cell Rep; 2022 Aug; 40(7):111181. PubMed ID: 35977490
[TBL] [Abstract][Full Text] [Related]
14. Identification of Targetable Liabilities in the Dynamic Metabolic Profile of
Gkountakos A; Centonze G; Vita E; Belluomini L; Milella M; Bria E; Milione M; Scarpa A; Simbolo M
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203491
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]